Optimal management of the hepatitis B patient who desires pregnancy or is pregnant

Current Hepatitis Reports

Volumn 11, Issue 2, 2012, Pages 82-89

  Bzowej, Natalie H ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

Antiviral; Hepatitis B; Lamivudine; Nucleoside; Nucleotide; Perinatal transmission; Pregnancy; Telbivudine; Tenofovir; Treatment

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BIRTH DEFECT; BREAST FEEDING; CESAREAN SECTION; DECOMPENSATED LIVER CIRRHOSIS; DRUG CLASSIFICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FDA PREGNANCY CATEGORIES; FIRST TRIMESTER PREGNANCY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOPROPHYLAXIS; INFECTION RATE; LACTIC ACIDOSIS; LIVER FIBROSIS; MEDICAL DECISION MAKING; NONHUMAN; PASSIVE IMMUNIZATION; PREGNANCY; PRENATAL DRUG EXPOSURE; REGISTER; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VACCINATION; VERTICAL TRANSMISSION; VIRUS LOAD;

EID: 84865763518     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-012-0130-x     Document Type: Article

References (55)

1. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (Revised August 2004). Available at http://www.who.int/mediacentre/ factsheets/fs204/en/
2. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut 1996;38:S39-S42.
3. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:1-36.
4. McMahon BJ, Alward WL, Hall DB et al. Acute hepatitis B virus infection: relation to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
5. Tassopoulos NC, Papavangelou GJ, Sjogren MH et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987;92:1844-50.
6. Chang MH. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000;15(suppl);E16-E19.
7. Keeffe EB, Dieterich DT, Han SB et al. A treatment algorithm for the management of chronic hepatitis B in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-41.
8. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
9. Marcellin P, Heathcote EJ, Buti, M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. 2008;359:2442-55.
10. The Antiretroviral Pregancy Registry Interim Report for 1 January 1989 through 31 July 2011. Available at http://www.apregistry.com/forms/interim- report.pdf.
11. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-89.
12. Munderi1 P, Helen Wilkes H, Tumukunde D et al. Pregnancy rates & Outcomes among women on triple-drug antiretroviral therapy in the DART trial [Poster WEPEB261]. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa.
13. FDA Pregnancy class definitions. Available at http://www.fda.gov/Drugs/
14. Ayres A, Yuen L, Manoharan S et al. Lamivudine in late pregnancy for prevention of HBV transmission: effectiveness and detection of antiviral resistance. EASL 2011. Abstract #736.
15. Berg T, Marcellin P, Zoulim F et al. Tenofovir is effective a monotherapy or in combination with emcitritabine in adefovir treated patients with chronic hepatitis B infection. Gastroenterology 2010.
16. Lai CL, Gane E, Liaw YF et al. Telbivudine verus lamivudine in patients with chronic hepatitis B. NEJM 2007;357:2576-88.
17. Nguyen G, Garcia RT, Nguyen N et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009;29:755-64.
18. de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
19. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
20. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002;51:597-99.
21. Beasley RP, Hwang LY, Lin CC et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised doubleblind placebo-controlled trial. Lancet 1981;2:388-93
22. Beasley RP, Hwang LY, Stevens CE. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized doubleblind, placebo-controlled trial. Hepatology 1983;3:135-41.
23. Beasley RP, Hwang LY, Lee GC et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2:1099-102.
24. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.
25. Zou H, Chen Y, Duan Z, Zhang H, Pan C. A retrospective study for clinical outcome of caesarean section on perinatal transmission of hepatitis B virus in infants born to HBeAg positive mothers with chronic hepatitis B (CHB). Hepatology 2010;52:235A.
26. del Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-30.
27. Wiseman E, Fraser MA, Holden S et al. Perinatal transmission of hepatitis B virus: an Australian experience. MJA 2009;190:489-92.
28. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudine combination for prevention of maternalinfant transmission of HIV-1. JAMA 2001;285:2083-93.
29. Gupta R, Warren T,Wald A. Gential herpes. Lancet 2007;370:2127-37.
30. van Zonneveld M, van Nunen AB, Niesters HG et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-7.
31. Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94-103.
32. Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review andmeta-analysis. Obstet Gynecol 2010;116:147-59.
33. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003;9:1501-3.
34. Shi M, Li X, He J et al. Lamivudine in interruption of HBV intrauterine infection. Clin Med Chin 2005;21:77-8.
35. Han ZH, Chen YH, Li LW et al. Effect and safety of preventing HBV vertical transmission bt lamivudine treatment. Clin J Intern Med 2005;44:378.
36. Li WF, Jiang R, Wie Z, Li Y. Clinical effect and safety of lamivudine in interruption of chronic HBV maternal to infant transmission. Chin Hepatol 2006;11:106-7
37. Feng HF, Zhang SF. Effecto on interruption of hepatitis B virus vertical transmission by lamivudine. J Appl Clin Pediatr 2007;22:1019-20.
38. Xiang GJ, Sun JW, Jiang SQ, Hu XB, Qu AL. Evaluation of therapeutic effect in HBV vertical transmission bt lamivudine treatment combined with active-passive immunization for pregnant women. Clin Prac Med 2007;2:14-6.
39. Yang JH. The clinical observation of effect of lamivudine on blocking mother to infant transmission of chronic HBV. Int Med Health Guid News 2008;14:76-8.
40. Yang S, Liu M, Wang L. Effect of high viral hepatitis B virus DANN loads on vertical transmission of hepatitis B virus in late-pregnant women. Zhonghua Fu Chan Za Zhi 2008;43:329-31.
41. Shi Z, Li X, Yang Y, Ma L. Clinical research on the interruption of mother to child transmisison of HBV-a randomized, double-blind, placebo-controlled study. Unite for Site 6th Annual Global Health Conference. New Haven (CT): Yale University 2009.
42. Olivo, SA, Macedo LG, Gadotti IC et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 2008;88:156-75.
43. Han L, Zhang H-W, Xie J-X et al. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol 2011;17:4321-4333.
44. Zhang LJ, Wang L. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Zhongua gan zang bing za zhi=Zhonghua ganzangbing zazhi=Chinese journal of hepatology 2009;17:561-3.
45. Han, G-R, Cao, M-K, Zhao, W et al. A prospective and openlabel study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatology 2011;55:1215-1221.
46. Pan CQ, Han GR, Jiang HX et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012 (Epub ahead of print). This is a recent large, prospective, non-randomized, open-label study showing a reduction in perinatal transmission of hepatitis B with the use of telbivudine.
47. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002;359:1488-9.
48. Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX, Liu ZH, Wang FS. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol 2002;67:20-6.
49. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008;15:37-41.
50. Nguyen MH, Garcia RT, Trinh HA et al. Prevalence of hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B. Aliment Pharmacol Ther 2009;30(11-12):1365-2036.
51. Lamivudine package insert. Available at http://us.gsk.com/products/ assets/us-epivir.pdf
52. Tenofovir DF package insert. Available at www.gilead.com/pdf/viread-pi. pdf
53. Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2:740-1.
54. Hill JB, Sheffield JS, Kim MJ et al. Risk of hepatitis b transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002;99:1049-52.
55. Shi Z, Wang H, Schreiber A et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011;165:837-46.